Recommendations for Extralicence Application of Rapamycin in Tu Berous Sclerosis

Child Neurology
doi 10.20966/chn.2015.48.344
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Polish Society of Child Neurologists

Related search

Retraction: Mammalian Target of Rapamycin Inhibitors for Treatment in Tuberous Sclerosis

Korean Journal of Pediatrics
Child HealthPediatricsPerinatology
2013English

Treatment Recommendations for Interferon-Beta in Multiple Sclerosis

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1999English

Efficacy of Rapamycin in Tuberous Sclerosis–Associated Hypopigmented Macules

JAMA Dermatology
DermatologyMedicine
2015English

Recommendations for Cognitive Screening and Management in Multiple Sclerosis Care

Multiple Sclerosis
Neurology
2018English

Update of EULAR Recommendations for the Treatment of Systemic Sclerosis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2016English

Pnd104 - Recommendations for a National Multiple Sclerosis (Ms) Strategy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Rapamycin Prevents Epilepsy in a Mouse Model of Tuberous Sclerosis Complex

Annals of Neurology
Neurology
2008English

Successful Treatment of Subungual Fibromas of Tuberous Sclerosis With Topical Rapamycin

JAMA Dermatology
DermatologyMedicine
2014English

Topical Rapamycin for Angiofibromas in Patients With Tuberous Sclerosis: How Does It Work in Clinical Practice?

Plastic and Aesthetic Research
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy